NCT01288326View on ClinicalTrials.gov

Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes

CompletedOBSERVATIONAL

Enrollment

254

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

liraglutide

Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.

Trial Locations (1)

1070

Novo Nordisk Investigational Site, Brussels

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY